Novartis Defends Zelnorm Cardiovascular Safety Lawsuits

North America - United States

In 2007, the U.S. Food and Drug Administration requested that Novartis suspend marketing of its gastrointestinal drug Zelnorm amid possible questions with respect to cardiovascular safety data. Faegre Baker Daniels' drug and device product liability team served as national counsel to defend Novartis in the numerous products liability lawsuits brought following suspension, where plaintiffs claimed the drug caused heart attacks or strokes.

Faegre Baker Daniels 网站使用 Cookie 来提升您的浏览体验。